PMID- 34900739
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220429
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for 
      Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
PG  - 785102
LID - 10.3389/fonc.2021.785102 [doi]
LID - 785102
AB  - BACKGROUND: The present COVID-19 pandemic has tended toward normality. To provide 
      convenient, safe, and effective home treatment programs for patients with 
      recurrent ovarian cancer (ROC), the clinical efficacy and safety of poly 
      (ADP-ribose) polymerase inhibitor (PARPi) (including olaparib, niraparib, and 
      rucaparib) monotherapy as a maintenance treatment for platinum-sensitive ROC were 
      systematically evaluated. METHODS: Numerous electronic databases were 
      systematically searched for randomized controlled trials (RCTs) of PARPi 
      maintenance treatment for ROC that were published before June 2021. The primary 
      endpoints were overall survival (OS) and progression-free survival (PFS), and the 
      secondary endpoint was grade 3-4 adverse effects (AEs). After data extraction and 
      the quality evaluation of the included studies, Bayesian network meta-analysis 
      (NMA) was performed using R software. The ability of each treatment was ranked 
      using the surface under the cumulative ranking (SUCRA) curve. RESULTS: The 
      analysis included five studies and 1390 patients. The NMA results demonstrated 
      that compared with the placebo, olaparib and niraparib exhibited significant 
      benefits in the gBRCA-mutated population, and respectively reduced the risk of 
      death by 31% (HR = 0.69, 95% CI: 0.53-0.90) and 34% (HR = 0.66, 95% CI: 
      0.44-0.99). Olaparib, niraparib, and rucaparib were all found to be very 
      effective in prolonging PFS in patients with ROC. All three PARPi treatments 
      increased the number of grade 3-4 AEs in patients with ROC as compared with the 
      placebo. CONCLUSIONS: Overall, olaparib and niraparib maintenance treatment can 
      significantly prolong the OS of patients with gBRCA mutations. Furthermore, the 
      three investigated PARPi monotherapy maintenance treatments can prolong PFS 
      regardless of BRCA mutation status. Although the incidence of AEs in the 
      treatment groups was found to be significantly higher than that in the placebo 
      group, the patients in the treatment group tolerated the treatment. Home oral 
      PARPi treatment can balance tumor treatment and pandemic prevention and control, 
      and is the most convenient, safe, and effective home treatment method available 
      against the background of the current COVID-19 pandemic. SYSTEMATIC REVIEW 
      REGISTRATION: https://inplasy.com/inplasy-2021-6-0033/.
CI  - Copyright (c) 2021 Wang, Wu, Liu, Zhou, Zhao, Geng, Jiang, Zhang, Zhang, Han and 
      Du.
FAU - Wang, Hongmei
AU  - Wang H
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Wu, Meng
AU  - Wu M
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Liu, Haonan
AU  - Liu H
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Zhou, Hang
AU  - Zhou H
AD  - Department of Hematology, The First People's Hospital of Lianyungang, Jiangsu, 
      China.
FAU - Zhao, Yang
AU  - Zhao Y
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Geng, Yifan
AU  - Geng Y
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Jiang, Bo
AU  - Jiang B
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Zhang, Kai
AU  - Zhang K
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Han, Zhengxiang
AU  - Han Z
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
FAU - Du, Xiuping
AU  - Du X
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China.
LA  - eng
PT  - Systematic Review
DEP - 20211124
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8652073
OTO - NOTNLM
OT  - PARP inhibitors
OT  - maintenance treatment
OT  - monotherapy
OT  - network meta-analysis
OT  - ovarian cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/12/14 06:00
MHDA- 2021/12/14 06:01
PMCR- 2021/11/24
CRDT- 2021/12/13 18:07
PHST- 2021/09/28 00:00 [received]
PHST- 2021/11/04 00:00 [accepted]
PHST- 2021/12/13 18:07 [entrez]
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2021/12/14 06:01 [medline]
PHST- 2021/11/24 00:00 [pmc-release]
AID - 10.3389/fonc.2021.785102 [doi]
PST - epublish
SO  - Front Oncol. 2021 Nov 24;11:785102. doi: 10.3389/fonc.2021.785102. eCollection 
      2021.